Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Panagiotis T Diamantopoulos, MD PhD, Vassiliki Pappa, MD, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, Alexandra Kourakli, MD PhD, Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Elena E. Solomou, MD, Anastasia Pouli, MD PhD, Panagiotis Panagiotidis, MD PhD, Maria Dimou, MD PhD, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, MD MSc, Anna Vardi, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Georgia Kaiafa, MD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, PhD, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, MD PhD, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5427.

https://doi.org/10.1182/blood-2019-127417

Published: 2019

Journal Articles

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Frieda Kontsioti, PhD, Zoi Tsakiraki, MD, Sotirios Papageorgiou, MD PhD, Efthimia Mpazani, MD, Irene Glezou, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Athanasios Galanopoulos, MD PhD, Argiris Symeonidis, MD PhD, Nora-Athina Viniou, MD PhD, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, MD PhD, Periklis Foukas, MD PhD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5403.

https://doi.org/10.1182/blood-2019-122424

Published: 2019

Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD

Blood (2019) 134 (Supplement_1): 5417.

https://doi.org/10.1182/blood-2019-131003

Published: 2019

Journal Articles

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, PhD, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, MD PhD, Evangelia Nakou, Anastasia Hadzidimitriou, PhD, George Kassiotis, Elli Papaemmanuil, PhD, Ioannis Mitroulis, Ioannis Kotsianidis

Blood (2019) 134 (Supplement_1): 2988.

https://doi.org/10.1182/blood-2019-126504

Published: 2019

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Lisa Pleyer, Michael Leisch, MD, Alexandra Kourakli, MD PhD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Blanca Xicoy, MD MSc, Jennifer Kaivers, MD, Johanna Ungerstedt, MD PhD, Sonja Heibl, MD, Peristera Patiou, MD, Anthony M. Hunter, MD, Elvira Mora, MD, Klaus Geissler, MD, Maria Dimou, MD PhD, María-José Jimenez, MD, David Kiesl, MD, Nora-Athina Viniou, MD PhD, Bhumika J. Patel, MD, Montserrat Arnan Sangerman, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD PhD, Athanasios Galanopoulos, MD PhD, Marisa Calabuig, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, MD PhD, Jaroslav Cermak, MD PhD, Andres Jerez, Julia Montoro, MD, Albert Cortés, Alejandro Avendaño Pita, MD, Bernardo López Andrade, MD, Eva Hellstrom Lindberg, MD PhD, Ulrich Germing, MD, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Argiris Symeonidis, MD PhD, Guillermo F. Sanz, MD PhD, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 844.

https://doi.org/10.1182/blood-2019-123941

Published: 2019

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Increased Age-Related B-Cells in Patients with Aplastic Anemia

Elena E. Solomou, MD, Eva Plakoula, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Athina Vyniou, Giannakoulas Nikolaos, MD, Maria D. Palasopoulou, MD, Evgenia Verigou, George Vassilopoulos, MD PhD, Haralambos Gogos, MD, Antonis Kattamis, Stamatis-Nick Liossis, MD

Blood (2018) 132 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2018-99-115120

Published: 2018

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Nora Viniou, MD, Athanasios Galanopoulos, MD PhD, Kalliopi Zafeiropoulou, Kotsianidis Ioannis, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 3825.

https://doi.org/10.1182/blood.V130.Suppl_1.3825.3825

Published: 2017

Journal Articles

The Effect of 5-Azacitidine Treatment on the Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes

Ioannis Liapis, Aristea Batsali, Anastasios Mitrakos, Elisavet Kouvidi, Athanasios Galanopoulos, MD PhD, Charalampos Pontikoglou, MD PhD, Emmanouil Kanavakis, Helen A. Papadaki, MD PhD

Blood (2017) 130 (Supplement 1): 4242.

https://doi.org/10.1182/blood.V130.Suppl_1.4242.4242

Published: 2017

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 4252.

https://doi.org/10.1182/blood.V130.Suppl_1.4252.4252

Published: 2017

Journal Articles

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Panagiotis Theodorou Diamantopoulos, MD PhD, Ioannis Kotsianidis, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Dimitrios Gogos, Paraskevi Roussou, Helen A. Papadaki, MD PhD, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sossana Delibasi, Menelaos Konstantinos Papoutselis, Alexandra Kourakli, MD, Dimitrios Tsokanas, Niki Rougala, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2974.

https://doi.org/10.1182/blood.V130.Suppl_1.2974.2974

Published: 2017

Journal Articles

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Athanasios G. Galanopoulos, MD PhD, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, MD PhD, Alexandra Kourakli, MD, Vassiliki Pappa, MD, Thomas Tsiambalis, Anastasia Pouli, MDPhD, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, Stamatis Karakatsanis, Kalliopi Zafeiropoulou, Maria Dimou, Theodoros P. Vassilakopoulos, MD PhD, Anna Vardi, MD PhD, Dimitrios Tsokanas, George Drakos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Elena E. Solomou, MD PhD, Georgia Kaiafa, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, George Vassilopoulos, MD PhD, Vasileios Lazaris, Athanasios Galanopoulos, MD PhD, Panagiotis Theodorou Diamantopoulos, MD PhD, Flora Kontopidou, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos Hatzitolios, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2979.

https://doi.org/10.1182/blood.V130.Suppl_1.2979.2979

Published: 2017

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

Journal Articles

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2017) 130 (Supplement 1): 1701.

https://doi.org/10.1182/blood.V130.Suppl_1.1701.1701

Published: 2017

Journal Articles

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 1693.

https://doi.org/10.1182/blood.V130.Suppl_1.1693.1693

Published: 2017

NARROW

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Increased Age-Related B-Cells in Patients with Aplastic Anemia

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

The Effect of 5-Azacitidine Treatment on the Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only